Activating mutations of CTNNB1, which codes β-catenin, have been detected in 11%–37% of HCC patients, and inactivating mutations of Axin1 or APC exist in approximately 5%–15% or 1%–2% of liver cancer specimens, respectively, acting as negative regulators9. This evidence concerns the gene AXIN1 and hepatocellular carcinoma.